Biologics/Immunotherapy News

A single dose of the novel antibody combination, REGN5713/14/15, appeared well-tolerated and demonstrated rapid and sustained inhibition of birch allergy symptoms, according to phase 1 study results.

Omalizumab effectively treated chronic cold urticaria and prevented further episodes of anaphylaxis, according to a single-center study published in The Journal of Allergy and Clinical Immunology: In Practice.

Dupilumab improved patient-reported taste compared with placebo among those with chronic rhinosinusitis with nasal polyps, according to study results presented during the European Academy of Allergy and Clinical Immunology Annual Meeting.

Omalizumab may effectively treat idiopathic anaphylaxis in patients without indication of mast cell clonality and who have failed on prior treatments, according to study results published in Annals of Allergy, Asthma & Immunology.

Dupilumab effectively treated nasal polyposis with minimal toxicity among treatment-refractory patients in a real-world setting, according to results of a retrospective cohort study published in Annals of Allergy, Asthma & Immunology.

Some monoclonal antibodies used in the treatment of inadequately controlled severe asthma may pose anaphylactic risks, according to a retrospective study of post-marking surveillance data published in Clinical and Translational Allergy.

Tezepelumab reduced exacerbations, improved lung function and reduced biomarkers in patients with severe, uncontrolled asthma with or without perennial allergies, according to a post hoc analysis of the phase 2b PATHWAY study.

May is Asthma and Allergy Awareness Month, “a perfect time” for primary care physicians to brush up on the best approaches to diagnosis and treatment, according the president-elect of the American College of Allergy, Asthma and Immunology.

The FDA has approved a self-injectable formulation of Xolair for appropriate patients with moderate to severe persistent allergic asthma, nasal polyps or chronic idiopathic urticaria, according to the manufacturers.

In a new study, adherence to asthma biologic therapy was higher than adherence to inhaled corticosteroids among adults with asthma.